Dieses Maus Monoklonal-Antikörper erkennt spezifisch ACE2 in WB, ELISA und FACS. Er zeigt eine Reaktivität gegenüber Human und wurde in 4+ Publikationen erwähnt.
Chaouat, Brizic, Kucan Brlic, Atari, Kliker, Alfi, Mandelboim, Wolf, Tafish, Kol, Jonjic, Mandelboim: "Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern." in: iScience, Vol. 25, Issue 9, pp. 104935, (2022) (PubMed).
Buchrieser, Dufloo, Hubert, Monel, Planas, Rajah, Planchais, Porrot, Guivel-Benhassine, Van der Werf, Casartelli, Mouquet, Bruel, Schwartz: "Syncytia formation by SARS-CoV-2-infected cells." in: The EMBO journal, pp. e106267, (2020) (PubMed).
Zulli, Rai, Buxton, Burrell, Hare: "Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34-positive cells in rabbit atherosclerotic plaques." in: Experimental physiology, Vol. 93, Issue 5, pp. 564-9, (2008) (PubMed).
Target
ACE2
(Angiotensin I Converting Enzyme 2 (ACE2))
Andere Bezeichnung
ACE2
Hintergrund
ACE2 has direct effects on cardiac functions. It is expressed predominantly in vascular endothelial cells of the heart and kidney. ACE2 converts angiotensin I to angiotensin 1-9. ACE2 was also identified as a functional receptor for SARS coronavirus.